Intelligent Bio Solutions Inc. (INBS) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for INBS, including 5 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published Nov 10, 2026.
Financial highlights
Full financials- Revenue, TTM
- $4.50M
- Revenue growth
- +36.5%
- Net income, TTM
- -$12.12M
- Net margin
- -269.5%
- Cash
- $5.93M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks42+133%
2026-05-172026-11-08
Mix2590d
- SEC Filings17(68%)
- Other5(20%)
- Earnings2(8%)
- Offering1(4%)
Activity · 52 weeks8655 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECIntelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECSEC Form 10-Q filed by Intelligent Bio Solutions Inc.10-Q - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- PRIntelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year GrowthRevenue up 25% year-over-year and 21% sequentially, marking third consecutive quarter above $1 million Higher-margin cartridge sales grew 32% year-over-year and 35% sequentially, representing 61% of total revenue Gross profit margin expanded to 54.5%, up from 46.6% in the prior-year quarter Company submitted its FDA 510(k) premarket notification during the quarter, a key step toward planned U.S. market entry NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlights for the f
- PRIntelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that management will present at the Webull Biotech Webinar on Thursday, November 12, 2026. Webull Biotech Webinar Date and Time: Thursday, November 12, 2026, at 2:00 P.M. ETSpeaker: Doug Heath, Vice President of Global SalesType: Virtual Presentation followed by Live Q&ARegistration: Link Here To schedule a one-on-one meeting with the INBS management team, please email KCSA Strategic Communications at INBS@kcsa.com. About Intelligent Bio Solutions Inc. Intelligent
- SECSEC Form DEF 14A filed by Intelligent Bio Solutions Inc.DEF 14A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECSEC Form PRE 14A filed by Intelligent Bio Solutions Inc.PRE 14A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Intelligent Bio Solutions Inc.10-K/A - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECSEC Form 8-K filed by Intelligent Bio Solutions Inc.8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECSEC Form EFFECT filed by Intelligent Bio Solutions Inc.EFFECT - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECSEC Form 424B3 filed by Intelligent Bio Solutions Inc.424B3 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECSEC Form S-3 filed by Intelligent Bio Solutions Inc.S-3 - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECSEC Form D filed by Intelligent Bio Solutions Inc.D - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECIntelligent Bio Solutions Inc. filed SEC Form 8-K: Other Events8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- PRIntelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ETNEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will host a virtual fireside chat on Thursday, September 24, 2026, at 4:30 p.m. ET. The moderated discussion will feature Harry Simeonidis, President and CEO, and Peter Passaris, Vice President of Product Development. Topics will include the Company’s FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, the supporting clinical data, the FDA review process, and the Company’s commercial progress outside the United States. Event Detail
- SECIntelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- PRIntelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market ClearanceNEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA), seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System (the "System") for detection of the opiate codeine. The submission represents the culmination of data from a structured, multi-study clinical program that the Company has executed throughout 2026, targeting entry into the multi-billion-dollar U.S. drug screening market. The Company’s 51
- SECIntelligent Bio Solutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECIntelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- PRIntelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) SubmissionNEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the results of its latest Method Comparison Study for its Intelligent Fingerprinting Drug Screening System (the "System") to detect the opiate codeine. Conducted across three independent U.S. clinical sites, the study represents the most comprehensive evaluation of the System in the Company's FDA 510(k) clinical study program. The study results show substantially improved performance compared to the Company's prior Method Comparison Study, announced in November of 2024
- PRIntelligent Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under Nasdaq RulesNEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (NASDAQ:INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has entered into a securities purchase agreement with a single existing institutional investor to issue, in a private placement priced at-the-market under Nasdaq rules, 2,036,659 shares of common stock (or Series M pre-funded warrants in lieu thereof), Series N-1 warrants to purchase up to an aggregate of 2,036,659 shares of common stock, and Series N-2 warrants to purchase up to an aggregate of 2,036,659 shares of common stock, at a combined purchase price of
- SECIntelligent Bio Solutions Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECIntelligent Bio Solutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- SECSEC Form 10-K filed by Intelligent Bio Solutions Inc.10-K - INTELLIGENT BIO SOLUTIONS INC. (0001725430) (Filer)
- PRIntelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge GrowthReader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year 502 active customers as of June 30, 2026, reflecting continued commercial momentum across safety-critical industries Company made substantial progress toward FDA clearance and planned market expansion during the year NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results and operational highlig
- PRIntelligent Bio Solutions Strengthens Quality Management Credentials with ISO RecertificationNEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its Intelligent Fingerprinting Drug Screening business has been recertified to the ISO 13485:2016 quality management system standard, the internationally recognized benchmark for medical device manufacturers. The recertification, issued by the British Standards Institution (BSI), is effective October 14, 2026, and will be valid for three years. On February 2, 2026, the U.S. FDA's amended Quality Management System Regulation (QMSR) came into effect, formally updati
INBS FAQ
9 questionsWhat is the latest news on INBS?
In the last 30 days Quantisnow tracked 7 wire items for INBS: 5 SEC filings, 1 press release or news item and 1 earnings update. The most recent was published on November 10, 2026.What is INBS revenue?
Intelligent Bio Solutions Inc. (INBS) reported $4.50M of revenue for the twelve months ended Sep 30, 2026. That is up 36.5% from the year before. Revenue for fiscal 2026 was $4.22M.Is INBS profitable?
No. Intelligent Bio Solutions Inc. reported a net loss of $12.12M for the twelve months ended Sep 30, 2026.How much cash and debt does INBS have?
Intelligent Bio Solutions Inc. reported $5.93M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does INBS stock trade?
Intelligent Bio Solutions Inc. (INBS) is listed on NASDAQ.What sector and industry is INBS in?
Intelligent Bio Solutions Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Intelligent Bio Solutions Inc. go public?
Intelligent Bio Solutions Inc. (INBS) completed its IPO in 2020.What companies are similar to INBS?
Notable peers in the same industry include HAE (Haemonetics Corporation), ABT (Abbott Laboratories), BRKR (Bruker Corporation), QDEL (QuidelOrtho Corporation), DHR (Danaher Corporation). Compare INBS side-by-side with any of them on Quantisnow.How can I track INBS on Quantisnow?
Quantisnow aggregates Intelligent Bio Solutions Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INBS to receive live email and push alerts on every new disclosure.